Development of a dual hormone artificial pancreas device
Official title: Advanced Development of Gemini-DHAP
Funded at Sfc Fluidics, LLC · NIH-10892876 · Data updated 2026-11-12
This study is working on a new device called the Gemini-DHAP that automatically gives insulin and glucagon to help people with diabetes manage their blood sugar levels more easily and accurately.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sfc Fluidics, LLC NIH-funded |
| Lab location | 1 site (Fayetteville, United States) |
| Project start | July 25, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $944,944 |
| NIH project number | 5R44DK137702-02 |
| Project ID | NIH-10892876 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 21 and older with diabetes, particularly those who experience challenges in managing their blood glucose levels.
✕Less likely to help
Patients who do not have diabetes or those who are not suitable candidates for hormone therapy may not benefit from this research.
What this research studies
This research focuses on creating a new device called the Gemini-DHAP, which is designed to automatically deliver both insulin and glucagon to individuals with diabetes. Using advanced microfluidic technology, the device will respond to real-time glucose readings from a continuous glucose monitor, ensuring precise hormone delivery. The project will involve extensive testing in laboratory and animal models to optimize the device's performance before moving towards clinical trials. Collaborations with medical and regulatory experts will help streamline the path to commercialization.
Why it matters
Potential benefit: If successful, this research could lead to a more effective management system for diabetes, improving blood sugar control and reducing complications for patients.
How similar studies have gone: Previous research on dual hormone delivery systems has shown promise, indicating that this approach could be a significant advancement in diabetes management.
Where this research is happening
-
Sfc Fluidics, LLC
Fayetteville, United States Active
Researchers
- Principal investigator: Payne, Forrest — Sfc Fluidics, LLC
- Study coordinator: Payne, Forrest
Related research
Other NIH-funded projects on the same topics.
-
Phenolics-Depleting Chip to improve insulin pumps
A small, low-power chip is being developed to remove phenolic compounds from insulin before it is delivered by a wearable insulin pump, with the goal of reducing irritation and extending device life.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.